×
About 31,983 results

ALLMedicine™ Lymphomas Center

Research & Reviews  15,291 results

Anaplastic diffuse large B-cell lymphoma cytologically diagnosed in pleural effusion: R...
https://doi.org/10.1002/dc.24730
Diagnostic Cytopathology; AbdullGaffar B, Seliem R

Feb 25th, 2021 - Diffuse large B-cell lymphoma (DLBCL) has some rare special subtypes. Anaplastic variant has the immunophenotypic and genotypic features of DLBCL, and is characterized by the presence of large bizarre hallmark-like and Reed-Sternberg-Hodgkin-like ...

Low serum cholesterol levels predict inferior prognosis and improve prognostic index sc...
https://doi.org/10.1016/j.leukres.2021.106534
Leukemia Research; Tang J, Yin H et. al.

Feb 25th, 2021 - Peripheral T-cell lymphomas, unspecified (PTCL-U) is a heterogeneous group of non-Hodgkin lymphomas, arising from the transformation of mature, post-thymic T-cells. Prognostic index for PTCL-U (PIT) is based on Europeans and may not be applicable ...

Markers of Follicular Helper T Cells Are Occasionally Expressed in T-Cell or Histiocyte...
https://doi.org/10.1093/ajcp/aqaa249
American Journal of Clinical Pathology; Abukhiran I, Syrbu SI et. al.

Feb 24th, 2021 - Follicular helper T cell (TFH) markers are expressed in angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma of the TFH phenotype (PTCL-TFH). However, differential expression and coexpression of these markers in benign and othe...

see more →

Guidelines  87 results

Off-the-Shelf CAR-T Cell Therapy ALLO-501 Induces High Responses in Relapsed/Refractory B-Cell Lymphomas
https://www.onclive.com/conference-coverage/asco-2020/off-the-shelf-cart-cell-therapy-allo501-induces-high-responses-in-relapsed-refractory-bcell-lymphomas

May 29th, 2020 - The allogeneic chimeric antigen receptor (CAR)-T cell therapy ALLO-501, paired with the monoclonal antibody ALLO-647, has clinical activity and a manageable safety profile in patients with relapsed/refractory large B-cell or follicular lymphoma. T...

Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and...
https://doi.org/10.1016/j.annonc.2019.10.010
Annals of Oncology : Official Journal of the European Soc... Zucca E, Arcaini L et. al.

Jan 8th, 2020 - Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2020|Zucca E,Arcaini L,Buske C,Johnson PW,Ponzoni M,|diagnosis,epidemiology,therapy,

Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
https://www.sciencedirect.com/science/article/pii/S0923753419354651
Annals of Oncology; Zucca E,et al

Dec 31st, 2019 - This updated ESMO Clinical Practice Guideline provides key recommendations on the management of marginal zone lymphomas.

Diffuse Large B-Cell Lymphoma: ESMO Clinical Practice Guidelines
https://www.esmo.org/Guidelines/Haematological-Malignancies/Diffuse-Large-B-Cell-Lymphoma
Annals of Oncology; Tilly H et al

Nov 13th, 2019 - Diffuse large B-cell lymphoma is relatively common and represents 30%–58% of non-Hodgkin’s lymphomas. The updated ESMO Clinical Practice Guidelines provide information on the current management of diffuse large B-cell lymphoma including recommenda...

see more →

Drugs  81 results see all →

Clinicaltrials.gov  15,879 results

Anaplastic diffuse large B-cell lymphoma cytologically diagnosed in pleural effusion: R...
https://doi.org/10.1002/dc.24730
Diagnostic Cytopathology; AbdullGaffar B, Seliem R

Feb 25th, 2021 - Diffuse large B-cell lymphoma (DLBCL) has some rare special subtypes. Anaplastic variant has the immunophenotypic and genotypic features of DLBCL, and is characterized by the presence of large bizarre hallmark-like and Reed-Sternberg-Hodgkin-like ...

Low serum cholesterol levels predict inferior prognosis and improve prognostic index sc...
https://doi.org/10.1016/j.leukres.2021.106534
Leukemia Research; Tang J, Yin H et. al.

Feb 25th, 2021 - Peripheral T-cell lymphomas, unspecified (PTCL-U) is a heterogeneous group of non-Hodgkin lymphomas, arising from the transformation of mature, post-thymic T-cells. Prognostic index for PTCL-U (PIT) is based on Europeans and may not be applicable ...

Markers of Follicular Helper T Cells Are Occasionally Expressed in T-Cell or Histiocyte...
https://doi.org/10.1093/ajcp/aqaa249
American Journal of Clinical Pathology; Abukhiran I, Syrbu SI et. al.

Feb 24th, 2021 - Follicular helper T cell (TFH) markers are expressed in angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma of the TFH phenotype (PTCL-TFH). However, differential expression and coexpression of these markers in benign and othe...

see more →

News  641 results

CAR T-cell Products Shine in Real-World Setting, Reveal New Insights
https://www.medscape.com/viewarticle/946240

Feb 21st, 2021 - Real-world experience with chimeric antigen receptor (CAR) T-cell therapies for large B-cell lymphomas compares favorably with experience in commercial and trial settings and provides new insights for predicting outcomes, according to Paolo Corrad...

FDA Approves Umbralisib (Ukoniq) for Two Lymphomas
https://www.medscape.com/viewarticle/945426

Feb 7th, 2021 - The US Food and Drug Administration (FDA) has granted accelerated approval to umbralisib (Ukoniq) for the treatment of adults with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen and...

FDA OKs New CAR T- Cell Tx for Large B-cell Lymphomas
https://www.medscape.com/viewarticle/945417

Feb 4th, 2021 - The US Food and Drug Administration (FDA) has approved lisocabtagene maraleucel (Breyanzi), a chimeric antigen receptor (CAR) T-cell product for the treatment of adults with certain types of relapsed or refractory large B-cell lymphoma who relapse...

Allogeneic Transplant: Durable Remissions in T-Cell Lymphomas
https://www.medscape.com/viewarticle/942195

Dec 7th, 2020 - In patients with T-cell lymphoma, allogeneic transplant can lead to durable remissions among patients who might otherwise have poor outcomes, results of a large retrospective observational study suggest. Five-year progression-free survival (PFS) a...

Pigment Traits, Sun Sensitivity Tied to Risk for Blood Cancers
https://www.medscape.com/viewarticle/941593

Nov 24th, 2020 - Risk factors for keratinocyte carcinomas, primarily pigment traits and sun sensitivity, were associated with the risk of developing non-Hodgkin lymphomas (NHL) and chronic lymphocytic leukemia (CLL) in an analysis of 92,097 women in France. The pr...

see more →

Patient Education  4 results see all →